Study of the TRIB2 protein network by Raposo, Catarina Martins
  
 
CATARINA MARTINS RAPOSO 
 
 
 
 
 
STUDY OF THE TRIB2 PROTEIN NETWORK 
 
 
 
 
 
 
 
 
UNIVERSIDADE DO ALGARVE 
Departamento de Ciências Biomédicas e Medicina 
2018 
  
 
CATARINA MARTINS RAPOSO 
 
 
 
 
 
STUDY OF THE TRIB2 PROTEIN NETWORK 
 
 
Master in Oncobiology – Molecular Mechanisms of Cancer 
This work was done under the supervision of 
Bibiana Ferreira, Ph.D 
Wolfgang Link, Ph.D 
 
 
UNIVERSIDADE DO ALGARVE 
Departamento de Ciências Biomédicas e Medicina 
2018 
  
  
  
 
 
 
 
 
 
 
 
STUDY OF THE TRIB2 PROTEIN NETWORK 
 
 
 
Declaração de autoria de trabalho 
Declaro ser a única autora deste trabalho que é original e inédito. 
Autores e trabalhos consultados estão devidamente citados no texto 
e constam da listagem de referências incluída.  
 
 
Catarina Martins Raposo 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2018 Catarina Martins Raposo 
 
A Universidade do Algarve reserva para si o direito, em conformidade 
com o disposto no Código do Direito de Autor e dos Direitos Conexos, 
de arquivar, reproduzir e publicar a obra, independentemente do 
meio utilizado, bem como de a divulgar através de repositórios 
científicos e de admitir a sua cópia e distribuição para fins meramente 
educacionais ou de investigação e não comerciais, conquanto seja 
dado o devido crédito ao autor e editor respetivos.
v 
 
 
Agradecimentos 
A realização desta dissertação de mestrado contou com diferentes apoios e 
incentivos sem os quais não teria sido possível concretizá-la. Passo a citá-los 
abaixo. 
Agradeço ao professor doutor Wolfgang Link por me ter recebido no seu 
laboratório e por toda a ajuda que, tão prontamente, sempre me deu. Pelo total 
apoio e disponibilidade. 
Agradeço à Bibiana por todos os ensinamentos e conselhos. Pelas opiniões e 
críticas. Pelas palavras de incentivo nos momentos menos felizes. 
Agradeço à Rita por toda a paciência. Por ouvir os meus desabafos e dar os 
melhores conselhos do mundo. 
Agradeço ao André. Pelo companheirismo, força e apoio nos instantes mais 
difíceis. Por tudo. 
Agradeço à Catarina Martins e ao André Fonseca. Agradeço à Susana Machado 
e ao João Santos. Agradeço ao Leonardo. Agradeço-vos por tornarem este ano 
mais leve. Sem vocês teria sido muito mais difícil. 
E por fim, agradeço muito aos meus pais. Sem eles este projeto não teria sido 
possível. Pelo apoio incondicional, incentivo e amizade. A eles dedico este 
trabalho! 
  
  
 
vii 
 
 
Abstract  
Melanoma is a highly aggressive type of cancer that arises from the 
transformation of melanocytes, the pigment-producing cells of the human skin. 
Metastatic melanoma is the deadliest form of skin cancer for which recently two 
treatment options have improved clinical outcome: targeted therapies and 
immunotherapy. However, the majority of patients primarily fail to respond or 
develop resistance to these drugs. The Link lab has discovered a novel 
mechanism of drug resistance facilitated by the oncoprotein TRIB2 via its direct 
interaction with AKT and consequently, AKT activation and AKT-dependent 
inactivation of FOXO and p53. Intriguingly, the tumor suppressor TRIB3 exerts 
the opposite effect on AKT. Therefore, we hypothesized that TRIB2 and TRIB3 
compete for AKT binding, determining the level of drug resistance. The current 
study was performed aimed at understanding the mechanism by which TRIB2 
and TRIB3 exert opposing effects on AKT. We used protein complementation 
assays and immunoprecipitation assays to characterize this mechanism. 
Our results show that TRIB3 is able to disrupt the association between TRIB2 
and AKT thus contributing to decrease the phosphorylation of the Serine 473 on 
AKT and preventing cell tumorigenesis. These findings are in concordance with 
literature describing TRIB3 as a tumour suppressor. 
Our data also demonstrate that increasing amounts of TRIB2 stabilize the 
association between TRIB3 and AKT. One possibility that might explain these 
observations is that in a cellular system with low levels of TRIB3, TRIB2 is able 
to bind and promote AKT activation. In a system with high levels of TRIB3, AKT 
preferentially interacts with TRIB3, preventing Serine 473 AKT phosphorylation. 
Therefore, we suggest that AKT has higher binding affinity to TRIB3 than to 
TRIB2. 
Understanding the resistance mechanism caused by TRIB2 and the role of TRIB3 
in preventing this mechanism is key to develop new and better therapies for 
patients with melanoma. 
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Resumo  
O melanoma é uma forma muito agressiva de cancro de pele que deriva da 
transformação maligna dos melanócitos - as células responsáveis pela produção 
de melanina que se encontram na camada basal da epiderme da pele humana. 
Apesar de representar apenas 5% de todos os tipos de cancro, o melanoma é 
responsável pela morte de 80% dos pacientes com cancro de pele. Para além 
disso, a incidência deste tipo de cancro tem aumentado muito nas últimas três 
décadas e a sua mortalidade aumenta de forma mais rápida do que qualquer 
outro tipo de cancro. 
Análises genéticas mostram que existem duas vias de sinalização frequente e 
comummente mutadas em tecido cutâneo de melanoma: a via MAPK e a via 
PI3K/AKT. Assim sendo, a alteração destas vias é importante no 
desenvolvimento e progressão deste tipo de cancro de pele, tendo como 
consequências o aumento da proliferação celular e também a resistência a 
fármacos que tenham como alvo proteínas presentes em qualquer uma destas 
vias de sinalização.  
Até há pouco tempo, o tratamento do melanoma metastático era realizado 
através de elevadas doses de interleucina-2 ou dacarbazina - dois fármacos 
quimioterapêuticos com taxas de sucesso que não superam os 20% e efeitos 
secundários muito severos. Nos últimos anos surgiram duas abordagens 
terapêuticas que se mostraram mais eficientes no tratamento do melanoma: as 
terapias dirigidas a membros da via MAPK (como o BRAF e o MEK) e também 
a imunoterapia que passa pela inibição de proteínas que controlam os 
checkpoints imunitários (como CTLA4, PD-1 e PD-L1). Embora estas 
abordagens se tenham mostrado mais eficientes no tratamento do melanoma 
metastático do que as anteriores, a maioria dos pacientes continua a não 
responder ou adquire resistência a estes tratamentos. Assim sendo, investigar a 
causa destes mecanismos de resistência é um passo muito importante para o 
desenvolvimento de terapêuticas novas mais eficazes.  
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Recentemente, o nosso grupo descobriu um novo mecanismo de resistência a 
uma série de medicamentos utilizados em ensaios clínicos ou já autorizados e 
prescritos para o tratamento do melanoma. Este mecanismo é mediado pela 
proteína TRIB2. TRIB2 codifica um dos três membros da família das proteínas 
pseudocinases tribbles. O nosso grupo identificou TRIB2 como um oncogene no 
contexto de melanoma e publicou dados importantes que mostram que, quer in 
vitro quer in vivo, a alta expressão de TRIB2 confere resistência a inibidores da 
via PI3K/mTOR e também a vários fármacos quimioterapêuticos como a 
dacarbazina. Para além disso a alta expressão de TRIB2 também confere 
resistência a inibidores de MEK e inibidores de imunocheckpoint. 
Mecanisticamente, o nosso grupo mostrou recentemente que TRIB2 promove a 
ativação de AKT, aumentando a fosforilação da serina 473 do AKT por mTORC2, 
via interação proteína-proteína. Esta ativação leva à inibição do supressor 
tumoral FOXO e ao aumento da atividade de MDM2, responsável por degradar 
o p53. Assim, a expressão dos genes alvo de FOXO e p53, que levariam à 
apoptose das células tumorais, está diminuída pelo aumento de TRIB2.  
Surpreendentemente, um grupo em Espanha com o qual mantemos uma estreita 
colaboração, liderado por Guillermo Velasco, demonstrou há bem pouco tempo 
que outro membro da família tribbles, TRIB3, parece ter o efeito oposto na 
ativação de AKT. O grupo sugere que TRIB3 funciona como um supressor 
tumoral e que a sua inativação leva a um aumento da tumorigénese.  
Uma vez que TRIB2 e TRIB3 parecem ter efeitos opostos na progressão das 
células tumorais, tendo funções contrárias na via de sinalização PI3K/AKT, 
então, o balanço da expressão de TRIB2 e TRIB3 é um fator importante na 
patogénese do melanoma e na resposta destes doentes à terapia. Assim sendo, 
a nossa hipótese é que TRIB2 e TRIB3 competem pela ligação a AKT. Para 
testar esta hipótese utilizámos o método PCA (Protein Complementation Assay) 
e ensaios de co-imunoprecipitação. 
Os nossos resultados de PCA mostram que o aumento de TRIB3 causa uma 
diminuição na associação entre TRIB2 e AKT na linha celular HEK293T, 
sugerindo assim que TRIB3 é capaz de perturbar a associação entre TRIB2 e 
AKT. Os nossos dados sugerem que, ao interferir na ligação TRIB2-AKT, TRIB3 
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inibe a fosforilação da Serina 473 do AKT (facilitada por TRIB2), prevenindo a 
sua ativação e evitando a malignidade das células. Este facto vai de encontro ao 
descrito em estudos anteriores sobre a função supressora tumoral de TRIB3. 
Este nosso projeto mostra assim, pela primeira vez, que os membros da família 
tribbles competem pela ligação a AKT. 
Por outro lado, ao contrário do que estávamos à espera, as nossas experiências 
de PCA mostram ainda que TRIB2 estabiliza a interação entre TRIB3 e AKT. 
Apesar de não existirem estudos na literatura acerca deste tópico, uma 
possibilidade que explique este facto é que, apenas em células que expressem 
pouco TRIB3, TRIB2 é capaz de ativar AKT. Em células com elevada expressão 
de TRIB3, o AKT liga-se preferencialmente a TRIB3, mantendo-se inativo. Estas 
experiências sugerem assim que a afinidade de ligação de AKT é 
consideravelmente maior por TRIB3 do que por TRIB2. 
Tentámos perceber, usando a técnica de western blot, se a diminuição da 
interação entre TRIB2 e AKT se refletiria, de facto, numa diminuição da 
fosforilação da Serina 473 do AKT mas os resultados foram inconclusivos devido 
a uma desigualdade no controlo de carga utilizado. Pensamos que este facto se 
deveu à grande quantidade de DNA transfetado para as células. Apesar disso, 
as únicas bandas comparáveis, parecem mostrar que células transfetadas com 
maior quantidade de TRIB3 têm menos ativação de AKT, o que vai de encontro 
aos resultados anteriores. 
Para ultrapassar este problema técnico decidimos utilizar a linha HEK293T, 
gerada anteriormente no nosso laboratório, que expressa estavelmente TRIB2 
para podermos diminuir a quantidade de DNA a ser transfetada nestas células. 
Tentámos validar os resultados do PCA utilizando co-imunoprecipitação nesta 
linha celular mas os resultados mostraram-se, mais uma vez, inconclusivos 
devido à falha de um controlo utilizado na experiência.  
Para, no futuro, validar esta hipótese num sistema mais representativo de 
melanoma, ou seja, em células onde normalmente exista a expressão de TRIB2, 
procedemos à criação de uma linha celular de melanoma: UACC-62 knock-out 
para o gene de TRIB2, utilizando a técnica de CRISPR-Cas9. Obtivemos vários 
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clones de células UACC-62 sem a expressão de TRIB2 que poderão ser 
comparados com a linha UACC-62 parental.  
Em suma, este projeto confirma o anteriormente descrito sobre a função 
supressora tumoral de TRIB3 e sugere que esta deriva de uma diminuição da 
interação entre TRIB2 e AKT causada por TRIB3, prevenindo a fosforilação e 
ativação de AKT. Neste estudo demonstrámos ainda que AKT se liga 
preferencialmente a TRIB3 em vez de TRIB2. 
Sugerimos um estudo aprofundado do mecanismo molecular pelo qual a 
interação de TRIB2 e AKT é perturbada por TRIB3 tendo em vista um melhor 
conhecimento do mecanismo de resistência provocado por TRIB2 em pacientes 
com melanoma. 
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1 Introduction 
1.1 Cancer 
Cancer is a leading cause of death worldwide. A study revealed that there were 
14.1 million new cases and 8.2 million deaths in 2012 [6]. Unfortunately, these 
numbers tend to increase. Cancer is set to become the major cause of morbidity 
and mortality in the coming decades. By 2030, 20.3 million new cancer cases and 
more than 13 million cancer deaths are expected [7].  
At the cellular level, cancer is viewed as a multistep process involving mutations 
and selection of cells with increasing proliferation, survival, invasion and 
metastatic capacity [8]. These mutations can affect oncogenes or tumor-
supressor genes operating similarly at the physiologic level: by increasing tumor 
cell number through the stimulation of proliferation or the inhibition of cell death. 
A third class of genes, known as stability genes or caretakers, include the 
mismatch repair (MMR), nucleotide-excision repair (NER) and base-excision 
repair (BER) genes and are responsible for repairing mistakes made during the 
replication of DNA or induced by exposure to mutagens [9]. When stability genes 
are inactivated, mutations occur at a higher rate [10]. 
In 2000 Hanahan and Weinberg suggested “a small number of molecular, 
biochemical, and cellular traits - acquired capabilities - shared by most and 
perhaps all types of human cancer”, widely known as the Hallmarks of Cancer. 
The first six hallmarks described included: self-sufficiency in growth signals, 
insensitivity to anti-growth signals, evading apoptosis, sustained angiogenesis, 
limitless replicative potential and tissue invasion and metastasis [11]. Eleven 
years later, in 2011 the same authors updated this list including two more 
hallmarks essential for malignant transformation: genomic instability and 
inflammation. In addition, there are two more capabilities emerging: the metabolic 
reprogramming and avoidance of the immune system, as shown in Figure 1 [4].  
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1.2 Melanoma 
Melanoma is the most aggressive skin cancer with constantly rising incidence 
worldwide, especially in fair-skinned populations, as represented in Figure 3. 
    
Figure 1 - The hallmarks of cancer. A normal cell needs to 
overcome several mechanisms to become transformed. The first 
described hallmarks were: self-sufficiency in growth signals, 
insensitivity to anti-growth signals, evading apoptosis, sustained 
angiogenesis, limitless replicative potential and tissue invasion and 
metastasis. In 2011 the same authors suggested two more 
hallmarks involved in tumorigenesis: genomic instability and tumor 
promoting inflammation. New capabilities have been emerging in 
the last years: the ability of cancer cells to reprogram its metabolism 
and to avoid the immune system mediated destruction. Adapted 
from Hanahan D. and Weinberg R., “The Hallmarks of cancer”, Cell, 
2011 [4] 
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Despite accounting for only 5% of all skin cancers, malignant melanoma is 
responsible for 80% of skin cancer deaths [12]. The World Health Organization 
(WHO) estimates that each year 132 000 new cases of melanoma are diagnosed, 
and this type of cancer has a mortality rate that continues to rise through the last 
years, as represented in Figure 2. 
Figure 3: Changes in annual lifetime risk of 
developing invasive melanoma in the United 
States from 1930 to 2016. Adapted from "Analysis 
of trends in US melanoma incidence and mortality", 
JAMA Dermatology, 2017 [3]. 
Figure 2: Estimated number of annual deaths from 
melanoma in the United States from 2009 to 2016. 
Adapted from "Analysis of trends in US melanoma 
incidence and mortality", JAMA Dermatology, 2017 [3]. 
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Melanoma arises from the transformation of the melanocytes - the pigment-
producing cells of the human skin that are localized within the basal layer of the 
epidermis. These cells are mainly found in the skin and hair follicles, but they also 
can be found in the ocular pigment epithelium. The main function of melanocytes 
is the synthesis, storage, and transfer of melanin pigments to the surrounding 
epithelial cells - resulting in the tanning response [13, 14]. 
Melanocytes are derived from the neural crest so, soon in embryonic 
development, these cells undergo epithelial to mesenchymal transition (EMT) to 
exit the neural tube and migrate to the skin of the whole body. In a similar way, 
malignant melanoma cells access the circulatory or lymphatic system and migrate 
to a new location, establishing metastases. Due to the fact that these cells just 
need to “remember how to migrate”, melanoma is known to be one of the most 
metastatic cancers and the 5-year survival rate of patients with metastatic 
melanoma is less than 5% [15, 16]. 
Apart from the family history, fair skin and immunosuppression, the major risk 
associated with melanoma progression is the ultraviolet (UV) radiation exposure. 
Solar radiation, UVA and UVB, can mutagenize DNA, often producing UV 
landmark mutations: C to T or CC to TT substitutions. When these mutations 
affect critical oncogenes and tumor-suppressor genes, transformation of 
melanocytes occur as shown in Figure 4 [17].  
 
 
Figure 4 - Cutaneous transformation of melanocytes. The accumulation of 
genetic changes induced by UV light both in tumor suppressor genes and 
oncogenes are responsible for the transformation of the pigment producing cells 
of the human skin. Adapted from Hussein, Mahmoud R., “Ultraviolet radiation and 
skin cancer: molecular mechanisms”, Journal of Cutaneous Pathology, 2005 [17]. 
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1.2.1  Clinical Grading System 
Staging of cancer is fundamental to provide physicians and patients with 
prognostic information and to guide therapeutic decisions [5]. Melanoma 
progression’s international staging system was developed by the American Joint 
Committee on Cancer (AJCC) and it categorizes melanoma into five different 
stages according to tumor thickness, number of metastatic nods and distant 
metastasis, as represented in Figure 5. 
 
1.2.2  Melanoma genetics 
The high prevalence of BRAF (50%) and NRAS (20%) mutations strongly 
correlate the RAS-RAF-MEK-ERK signalling, also known as MAPK pathway, with 
the aggressive biology of melanoma. However, both activating BRAF and NRAS 
mutations are found in tumors with very little malignant potential as benign nevi 
[18]. Furthermore, it has been shown that the expression of BRAF alone fails to 
transform benign melanocytes [19]. Finally, some tumors with resistance to BRAF 
inhibitors continue to survive and proliferate despite continued inhibition of the 
RAS-RAF-MEK-ERK signalling pathway [20]. Thus, the activation of the RAS-
Figure 5 - Stages of melanoma. The first stage is the less aggressive, 
cell proliferation is limited to the epidermis, not reaching the dermis so 
the treatment applied in this case in only the surgical resection. 
Melanomas on stages I and II are characterized by tumor thickness 
and ulceration and are treated by surgical resection followed by drug 
or radiation treatment. When cancer cells are already spread to the 
lymph nodes is stage III and surgical removal of the lymph nodes is 
required. If cancer has spread into distant organs it is a IV stage 
melanoma and is treated with chemotherapy [5]. 
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RAF-MEK-ERK alone is not sufficient to fully explain the pathogenesis of this 
aggressive cancer [21]. 
1.2.3 PI3K-AKT pathway 
Activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway is one of the 
most frequent events in cancer [22]. This pathway plays a significant role in 
melanoma, frequently in the setting of concurrent activation of MAP kinase 
pathway [21-24]. Furthermore, the activation of the PI3K-AKT pathway is 
correlated with poor clinical outcomes and resistance to MAPK pathway inhibitors 
used for melanoma treatment [25].  
The PI3K-AKT pathway can be activated by different factors including binding of 
ligands by receptor tyrosine kinases (RTKs), G protein-coupled receptors 
(GPCRs) and GTP binding of RAS proteins. Any of these signals can activate the 
catalytic activity of PI3K. Then PI3K phosphorylates the 3rd position of the inositol 
ring of lipids in the plasma membrane, resulting in the conversion of 
phosphatidylinositol-(3,4)-P2 (PIP2) to phosphatidylinositol-(3,4,5)-P3 (PIP3). 
PIP3 interacts with pleckstrin homology (PH) domains of intracellular proteins, 
resulting in its recruitment to the inner surface of the cellular membrane. One 
such protein is AKT, as shown on Figure 6 [21]. 
 
Figure 6 - The PI3K-AKT pathway. Diagram of key activators and regulators of 
the PI3K-AKT signalling network.  Adapted from Davies, Michael A., “The role of 
the PI3K-AKT Pathway in Melanoma”, The Cancer Journal, 2012 [21]. 
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AKT has 3 highly homologous isoforms: AKT1, AKT2 and AKT3. It is a serine-
threonine kinase that normally exists in the cytoplasm in an inactive form. Upon 
activation of PI3K, AKT is recruited to the plasma membrane (by its PH domain) 
and then it can be phosphorylated at 2 critical residues: Thr308 and Ser473. The 
Thr308 is phosphorylated by phosphoinositide-dependent kinase1 (PDK1), which 
also has a PH domain being recruited to the plasma membrane. Ser473 of AKT 
is phosphorylated by the mTORC2 complex in response to growth factor stimuli. 
AKT is activated in more than 60% of melanoma patients [26]. AKT can be 
inactivated by the phosphatases PP2A and PHLPP1/2. PTEN dephosphorylates 
the 3rd position of PIP3 directly antagonizing the activity of PI3K, as represented 
in Figure 6. In this sense, loss of PTEN, that occurs in up to 30% of melanoma 
patients, results in constitutive activation of the PI3K-AKT pathway [21, 27]. 
1.2.4  Melanoma treatment options 
Melanoma resection 
The first treatment choice for patients with early- and intermediate-stage of 
disease (stage I and stage II) is surgical resection. It consists on the resection of 
the entire melanoma and surrounding skin, including the epidermis, dermis and 
subcutaneous fat. 
The presence of cancer cells in regional lymph nodes is the most important 
prognostic indicator for melanoma patients [28]. Since the lymphatic system is 
the first rout of metastasis in melanoma, it provides information about the disease 
progression. Therefore, the identification and evaluation of the first node or nodes 
draining the primary melanoma along its lymphatic pathway which are called 
sentinel lymph nodes (SLN), is crucial for staging, prognostication and making 
treatment decisions [29]. If the presence of melanoma cells is confirmed in the 
lymphatic system the standard medical procedure is perform a complete 
lymphadenectomy to remove all the metastatic cells present in the lymphatic 
pathway [30]. 
Chemotherapy 
Chemotherapy has a more prominent role in melanomas which do not harbour 
somatic mutations that can be targeted with specific inhibitors. This type of 
therapy relies on inhibiting the division of rapidly growing cells, such as cancer 
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cells. However, rapid division rate also occurs in normal bone marrow cells, skin 
cells, gastrointestinal cells and hair follicle cells. Therefore, the fact that 
chemotherapeutic agents do not target specifically cancer cells is the major cause 
of associated toxicity and side effects of general chemotherapy [31]. 
The first chemotherapeutic agent used to treat patients with advanced melanoma 
was dacarbazine (DTIC) which is an alkylating agent. Treatment with DTIC 
results in DNA adducts, preventing the multiplication of rapidly growing cells. 
DTIC has an overall response rate between 10%-20% and allows a complete 
remission in only 5% of melanoma patients [32]. DTIC is an intravenous infusion 
and the main side effects include nausea, vomiting and myelosuppression. 
Another chemotherapeutic agent that is used in the treatment of advanced-stage 
melanoma is temozolomide (TMZ). Similar to DTIC, TMZ is an alkylating agent. 
It is an oral chemotherapeutic drug and due to its small weight, it can cross the 
blood-brain barrier, and is widely used to treat patients with melanoma metastasis 
in the brain [33]. The main side effects include headache, nausea, vomiting, 
lymphopenia and thrombocytopenia [34]. 
A randomized phase III trial of DTIC versus TMZ in patients with metastatic 
melanoma demonstrated similar survival response rates - 12.1% for DTIC-treated 
patients and 13.5% for temozolomide-treated patients. 
Other cytotoxic chemotherapeutic drugs have been tested for the treatment of 
advanced melanoma such as  nitrosaureas (Carmustine), vinka alcaloids 
(Vincristine), taxanos (Taxol) and platinium compounds (Cislatin) but have shown 
no benefits compared to DTIC or TMZ [35, 36]. 
 
Immunotherapy 
Chemotherapy regimens can be beneficial for some patients with advanced 
melanoma, but none have led to a significant improvement in overall survival. For 
this reason, additional treatment options have become available in the last years.  
Melanoma is a particularly immunogenic tumor what makes this type of cancer a 
good candidate for immunotherapy [37]. The ability of melanoma cells to induce 
an immune response is associated with the high mutation load of this type of 
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cancer, as shown in Figure 7. As mutational load depends on the exposure to 
carcinogens, tissues directly exposed to carcinogenic substances, such as skin 
and lung, tend to have a high mutational load. Melanoma has a high prevalence 
of somatic mutations leading to the presentation of several neoantigens on the 
cell surface of cancer cells. These neoantigens are seen as “strange epitopes” 
and trigger an immune response.  
 
Figure 7 - Signatures of mutational processes in human cancer. Cancer with 
high mutational load respond better to immunotherapy and tend to be highly 
resistant to traditional treatments. Adapted from “Signatures of mutational 
process in human cancer”, Nature, August 2013 [38]. 
 
Immunotherapy using checkpoint inhibitors is defined as the use of the patient 
immune system to treat cancer and it involves the inhibition of regulatory cell 
surface molecules which act normally to dampen or modulate T-cell activation.  
Interleukin-2 (IL-2) was one of the first immunotherapeutic drugs used since the 
1990´s but it is still not clear how IL-2 works as an anti-cancer therapy. It is 
thought that the exogenous IL-2 may promote a Cytotoxic T lymphocytes (CTL)-
mediated anti-tumor response [39]. IL-2 has shown some toxicity associated with 
vascular leak syndrome (VLS), which leads to interstitial edema and general 
organ failure [40]. Over the last years three new immunotherapeutic drugs have 
been approved by Food and Drug Administration (FDA) and many more are in 
clinical trials for the treatment of melanoma. The first of these drugs to be 
approved was Ipilimumab, an antagonist to CTLA-4 (Cytotoxic lymphocyte-
associated antigen 4). More recently antagonists of Programmed Cell Death 
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Protein 1 (PD-1) Nivolumab and Pembrolizumab followed. Both Nivolumab and 
Pembrolizumab negatively regulate the immune system, maintaining self-
tolerance and avoiding auto-immune response [41]. Cancer cells often take 
advantage of this regulatory immune mechanism, blocking immune responses 
against them. Anti-CTLA-4 antibodies bind to the CTLA-4 receptor, blocking its 
downstream signalling pathway thereby allowing T-cell activation and 
proliferation. Therefore, in the presence of this drug the immune system is 
capable of destroying melanoma cells in a subset of patients[42]. Similarly, PD-1 
is also an immune checkpoint protein found on the surface of cells. Upon binding 
to its two ligands PD-L1 and PD-L2, PD-1 negatively regulates the activity of T-
cells at a variety of stages of the immune response. When engaged by the 
ligands, PD-1 inhibits kinase signalling pathways that normally lead to T-cell 
activation [43]. [44, 45]. However, not all patients with melanoma respond to this 
treatment and it can have considerable side effects. Moreover, it is not possible 
to predict which patients are likely to respond to therapy and which patients are 
not. [46] 
Targeted therapies 
Targeted therapies interfere with a specific molecular target that drives cancer 
cell growth and survival. For melanoma treatment much attention has been 
focused on developing inhibitors of the most hyperactivated pathways in this type 
of cancer: MAPK and PI3K pathways. BRAF is a serine-threonine protein kinase 
belonging to the RAF family of kinases, which is part of the MAPK signalling 
pathway, represented in Figure 8. Under normal, non-cancerous conditions, 
binding of a growth factor to a RTK activates RAS, which in turn activates the 
RAF kinases: A-RAF, B-RAF and C-RAF. Activated RAF in turn phosphorylates 
and activates MEK, another kinase leading to its activation and the 
phosphorylation of the downstream kinase ERK and subsequent activation of 
several targets that result in cell proliferation and survival. The dysregulation of 
the MAPK pathway is a key event in the development of melanoma. Activating 
BRAF mutations are present in about 50% of all melanomas, most commonly, 
resulting in a substitution of a glutamic acid for a valine at position 600 (V600E) 
[47]. This mutation leads to a constitutive active MEK and thus, hyperactivated 
ERK.  
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The clinical outcome for patients with advanced melanoma carrying B-RAF 
mutations, significantly improved with the use of specific BRAF and MEK 
inhibitors. Two clinically relevant BRAF inhibitors are vemurafenib (Zelboraf) and 
dabrefinib (Tafinlar). Treatment of advanced melanoma patients harbouring the  
BRAFV600E mutation with vemurafenib, the first BRAF inhibitor approved by the 
FDA in 2011, resulted in tumor regression in over 80% of patients, having a 
positive impact on progression-free survival (PFS) and overall survival (OS) [48, 
49]. The mechanism of action of vemurafenib involves the selective inhibition of 
the mutated BRAFV600E kinase, reducing the MAPK signalling activity. The 
adverse effects associated with almost every patient treated with vemurafenib, 
include rash, fatigue, arthralgia, alopecia, photosensitivity and nausea. Despite 
the initial positive response to treatment with vemurafenib or dabrefenib, the 
durability of response is limited by the development of drug resistance by the 
patients in the next 6 to 8 months [50, 51]. There are several mechanisms by 
which cancer cells can reactivate the MAPK pathway but, in most cases, it is due 
to activating mutations on downstream targets of BRAF such as MEK and ERK 
[52]. Considering this, an alternative strategy would be to develop inhibitors of 
downstream effectors of BRAF, such as MEK inhibitors. 
Figure 8 - Overview of the MAPK pathway. Activation of a cell 
surface receptor tyrosine kinase (RTK) leads to a sequential 
phosphorylation and activation of proteins in the MAPK pathway: 
RAS, RAF, MEK and ERK. ERK activation mediates phosphorylation 
of key proteins involved in cellular proliferation and survival. Adapted 
from [2]. 
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The FDA approved the first MEK inhibitor, Trametinib, in 2013. Trametinib 
(Mekinist) is an orally available, small-molecule, selective inhibitor of MEK1/2 [53-
55]. In a phase 3 clinical trial, 322 patients with metastatic melanoma and BRAF 
mutations were randomized to receive either trametinib or chemotherapy (DTIC 
or paclitaxel). The OS rate at 6 months was 81% in the trametinib group and 67% 
in the chemotherapy group [56].  
Targeting the MAPK and PI3K/AKT signaling pathways in melanoma with 
selective inhibitors has produced remarkable antitumor activity. However, the 
development of resistance to these therapies remains a major barrier to complete 
tumor eradication [57].  
 
1.2.5 Resistance mechanisms 
Drug resistance is a phenomenon that results when disease become tolerant to 
pharmaceutical treatments. The mechanisms underlying resistance are 
represented in Figure 9 and include drug inactivation, drug efflux or the ability of 
cancer cells to increase the DNA damage repair [58]. Resistance mechanisms 
can be intrinsic or acquired. Intrinsic resistance means that it already existed 
before the treatment. Conversely, acquired resistance occurs after the treatment 
meaning that the tumor was initially sensitive to the therapy.  
Melanoma is one of the most therapy-resistant types of cancer. Despite the 
encouraging results of immune checkpoints inhibitors, the majority of patients are 
either intrinsically resistant or rapidly develop resistance to this therapy [59]. 
Similarly, melanoma patients treated with MAPK pathway inhibitors, develop 
resistance in less than a year [60]. Half of the patients treated with vemurafenib 
or dabrafenib monotherapy develop drug resistance within 6-8 months of 
treatment [61]. 
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Figure 9 - Resistance mechanisms to cancer therapy. The main mechanisms 
that can enable or promote direct or indirect drug resistance in human cancer 
cells include drug inactivation, drug efflux or the ability of cancer cells to increase 
the DNA damage repair. Adapted from [58]. 
Drug inactivation 
Many anticancer drugs must undergo metabolic activation before having clinic 
efficacy. However, some cancer cells can downregulate the enzymes responsible 
for drug activation. [62]. Important examples of drug activation and inactivation 
enzymes include the cytochrome P450 (CYP) system, a superfamily that 
activated or deactivates the drug [63, 64]. Mutations or alterations in constituents 
of the CYP system may change the proteins’ metabolic capabilities such as 
increasing the breakdown of drugs and their secretion by kidneys. Therefore, the 
drug intracellular levels would not be maintained and the cancer would be 
considered resistant to it [65]. 
Drug Efflux 
Reducing drug concentration by enhancing drug efflux is one of the most studied 
mechanisms of cancer drug resistance [66]. ATP-binding cassette (ABC) 
transporters are a superfamily of proteins responsible for the transport of a broad 
variety of drugs outside the cell. This mechanism plays an important role in 
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preventing accumulation of toxins within the cell but, in cancer conditions these 
proteins were found to be overexpressed removing the drug from the cell [67]. 
DNA damage repair 
In response to chemotherapy drugs that directly or indirectly damage DNA, DNA 
damage response (DDR) mechanisms can reverse drug-induced damage, 
inhibiting the apoptotic processes and cancer cell death [68]. Cisplatin, a 
platinium-containing chemotherapy drug, cause harmful DNA crosslinks in 
cancer cells, which can lead to apoptosis. Nucleotide excision repair (NER) and 
homologous recombination (HR) are the primary DNA repair mechanisms 
involved in reversing this damage, contributing to drug resistance in these cases 
[69]. 
Cell death inhibition 
Apoptosis has two established pathways: an intrinsic pathway mediated by the 
mitochondria that involves B-cell lymphoma 2 (BCL-2) family proteins and 
caspase-9, and an extrinsic pathway that involves death receptors on the cell 
surface. Both pathways merge through the activation of downstream caspase-3 
which ends up causing apoptosis [58]. In several types of cancers, such as 
melanoma, BCL-2 proteins, AKT and other anti-apoptotic proteins are more 
activated having a negative effect on apoptosis, allowing the survival of cancer 
cells and contributing to drug resistance [70]. 
Epithelial-Mesenchymal Transition and Metastasis 
The epithelial to mesenchymal transition (EMT) is a mechanism by which solid 
tumors become metastatic. It is a complex mechanism that can involve the 
formation of new blood vessels (angiogenesis), the reduction of the expression 
of cell adhesion receptors (integrins and cadherins, and the increase expression 
of cell adhesion receptors to induce cell motility [71]. The EMT has been found to 
play a critical role in cancer drug resistance but the nature of this link remains 
unclear [71].  
1.2.6 Tribbles 
The Link laboratory has discovered a novel mechanism of drug resistance, 
facilitated by the oncoprotein Tribbles homolog 2 (TRIB2), to a broad spectrum 
of drugs used in clinical trials (BEZ235, a PI3K/mTORC inhibitor, BAY236 and 
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BAY1082439, both PI3K inhibitors, rapamycin, a mTORC inhibitor) or which are 
already in use for melanoma treatment (DTIC, gemcitabine and 5-fluoruracil).  
The Tribbles (TRIB) pseudokinases proteins were first described in 2000 as major 
regulator of Drosophila morphogenesis by inhibiting mitosis. Tribbles were 
identified in a genetic screen that aimed to identify mutations that control cell 
division and cell migration during embryonic Drosophila development [72, 73].  
Tribbles encodes an evolutionary conserved family of proteins characterized by 
the presence of a N-terminal domain, a central serine-threonine kinase like 
domain, a C-terminal domain that contains a COP-1 binding domain for E3 
ubiquitin ligases and a MEK-1 binding domain which mediates the interaction with 
multiple MAPKKs proteins, as represented on Figure 10. Tribbles are considered 
catalytically inactive because they lack some conserved residues on the ATP 
(Adenosine Triphosphate) binding site. However, recent data suggested that 
TRIB2 has the ability to hydrolyse ATP in vitro, showing a weak kinase activity 
[74]. 
In mammals three genes of TRIB homologues have been described: TRIB1, 
TRIB2 and TRIB3. Tribbles family members are expressed in different tissues, as 
shown on Figure 11, and control multiple aspects of eukaryotic cell biology that 
include glucose and lipid metabolism, inflammation, cellular stress, survival, 
apoptosis and tumorigenesis [75].  
Figure 10 - Structure of Tribbles family. Tribbles structure has three main 
domains: a central serine-threonine kinase like domain (resembles a kinase 
domain but has some aminoacids lacking that are essential to the catalytic 
activity), a MEK-1 and a COP-1 binding domain. Adapted from [1]. 
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Figure 11 - Tribbles tissue expression. TRIB1 is highly expressed in the bone 
marrow, peripheral blood leukocytes, thyroid gland and pancreas [76, 77]. TRIB2 
is highly expressed in peripheral blood leukocytes, thymus, heart, brain, kidney, 
lung, skin and white adipose tissue [76, 77]. TRIB3 is more expressed in human 
liver [76].  
The mechanism of action of these proteins is not fully understood but it is thought 
that Tribbles function as scaffold proteins contributing to stabilize and support the 
modulation of signaling pathways as MAPK pathway. The atypical pseudokinase 
domain also retains a regulated binding platform for substrates which are then 
ubiquitinated by specific E3 ligases, facilitating the ubiquitin-mediated 
degradation of some proteins [1, 78]. 
Recently, the study of the formation of protein complexes involving tribbles that 
then dictate cellular signaling is an emerging theme in tribbles biology [1]. TRIB1 
and TRIB2 appear to function as oncogenes in acute myelogeneous leukemia 
(AML) [77]. Furthermore, the Link laboratory also correlated high levels of TRIB2 
with melanoma disease staging and clinical progression, suggesting TRIB2 as a 
biomarker for diagnosis and progression of melanoma patients [12]. TRIB3 has 
been proposed to act as an inhibitor of AKT, having a tumor suppressor activity 
[79]. 
The role of TRIB2 in melanoma prognosis 
TRIB2 was discovered to be a repressor of the tumor suppressor Forkhead BoxO 
(FOXO), through a screening for FOXO repressor proteins [80]. High levels of 
TRIB2 were shown to facilitate the growth and survival of melanomas by 
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deregulating FOXO activity [12]. As FOXO proteins play an important role in 
supressing cell survival and proliferation through regulation of the expression of 
apoptotic proteins and cell cycle regulators, proteins that are capable of 
supressing FOXO activity are strong candidates to have a direct role in cancer 
initiation, maintenance, progression and to confer drug resistance [81].  
Furthermore, the high TRIB2 protein levels found in melanoma patients were 
correlated with high AKT activation, more precisely - with high levels of 
phosphorylation of the serine 473 (Ser473) of AKT [82]. It has been demonstrated 
that the association between TRIB2, via the COP-1 domain, and AKT causes an 
increased phosphorylation of the serine 473 of AKT via mTORC2, activating AKT 
and culminating in high levels of cell proliferation and survival. Through these 
studies they demonstrated that cell lines with higher TRIB2 protein levels 
correlated with AKT activation through its phosphorylation on serine 473 and with 
increased total AKT. In melanoma cells with TRIB2 depletion the levels of 
phosphorylation of Ser473 of AKT and total AKT were lower compared to 
melanoma cells where TRIB2 was not depleted [82]. Furthermore, TRIB2 
overexpression increased the levels of AKT pSer473 and the levels of total AKT 
before and after the treatment with PI3K and mTOR inhibitors, suggesting that 
these drugs may not be clinically efficient in patients with high levels of TRIB2. 
Link et al suggested that TRIB2 and AKT interact, forming a protein complex and 
promoting AKT activation [82]. AKT activation leads to the phosphorylation of 
FOXO3a (a tumor suppressor gene) for proteasome degradation and also 
activates E3 ubiquitin ligase mouse double minute 2 homologue (MDM2) with 
consequent inhibition of apoptosis mediated by p53 [83]. MDM2 functions as a 
E3 ligase that ubiquitinates p53 for degradation blocking its transcriptional activity 
and culminating in uncontrolled cancer cell proliferation [82, 84].  
The role of TRIB3 in cancer 
Intriguingly, tribbles pseudokinase 3 (TRIB3) has been proposed to exert the 
opposite effect on AKT by other groups, including one of our collaborators from 
England, Dr. Endre Kiss-Tooth [85-87]. 
TRIB3 has been proposed to act as an inhibitor of AKT although the precise 
molecular basis of this activity and whether the loss of TRIB3 contributes to 
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cancer initiation and progression remain to be clarified. TRIB3 has been 
suggested to interact with different targets including MAPKs and several 
transcription factors [85].  
It has been shown that the genetic inhibition of TRIB3 facilitates oncogene 
transformation and enhances the tumorigenicity of cancer cells, suggesting that 
TRIB3 has an oncossupressive function. TRIB3 has also been shown to interact 
and inhibit AKT [86, 87]. In addition, the loss of TRIB3 enhances the 
phosphorylation of AKT in cancer cells via mTORC2, promoting FOXO 
inactivation [79]. Moreover, TRIB3 is found to be focally deleted in tumors of 
epithelial origin and in breast cancer patients. In addition, analysis of gene 
expression profiles of cancer patients from published studies reveals that TRIB3 
mRNA levels are downregulated in different tumor types [79]. 
 
1.3 Hypothesis 
TRIB2 and TRIB3 are proposed to play an opposing role in tumorigenesis by 
controlling the PI3K/AKT pathway so the balance between TRIB2 and TRIB3 
expression may be a critical factor underlying melanoma pathogenesis and 
response to therapy. Taking this into account we hypothesize that TRIB2 and 
TRIB3 compete for AKT binding. 
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2 Methodology 
2.1 Cell culture 
Cell culture is a tool by which the behaviour of the cells can be studied 
independent of the whole organism. In this method cells are grown under 
controlled, favourable and artificial conditions providing an important system to 
study a range of diseases. 
All the procedures below were performed under sterile conditions using a Laminar 
Flow Chamber (Microflow, advanced biosafety cabinet class II, UK). The cell lines 
used in this study were maintained using Dulbecco’s Modified Eagle’s Medium 
(DMEM) with Ultraglutamine and 4.5 g/L Glucose (Lonza, Verviers, Belgium) 
supplemented with 10% Fetal Bovine Serum (FBS;Biowest, South America) and 
1% Penicillin/Streptomycin (Amresco, Ohio).  The cells were cultured in 10 cm 
plates (SLP Life Sciences, Korea) and maintained in an incubator (Thermo 
Electron Corporation 311, Canada) at 37 ºC and 5% carbon dioxide (CO2). When 
cells reached 70-80% confluency they were detached from culture flasks and 
replated onto new culture flasks. Cells were washed with 1x Phosphate Buffered 
Saline (PBS; Sigma Aldrich, USA) and coated with 1.5x trypsin (Sigma Aldrich, 
USA) diluted in 1x PBS. Trypsin is a member of serine protease family and, by 
cleaving peptides, trypsin allows cells to detach from the culture plate. 
2.1.1 Cell count 
To plate a specific number of cells, they were counted using a Neubauer chamber 
(Blau brand, Germany). We used 10 µL of the cell suspension and mixed it with 
10 µL of Trypan Blue (Sigma Aldrich, UK). Then we transferred 10 µL of the 
solution to the Neubauer chamber and we counted the number of cells present in 
the four external corners, represented on Figure 12. 
Study of the TRIB2 protein network 
Catarina Martins Raposo © 2018 
 
24 
 
Cell concentration was calculated according to the following equation 
(X1+X2+X3+X4)/4x2x104 cells/ml. It means that we divided the average number of 
cells present in every square for the dilution factor of our solution and then we 
divided the result by the volume of the chamber (it has 0.1mm of depth so the 
volume is 0.1mm3 that is converted to 0.1µL or 10-4ml). 
2.1.2  Cell lines  
For this study we used cell line derived from Human Embryonic Kidney (HEK) 
293T cells and UACC-62 (a malignant melanoma cell line). Both provided by 
American Type Culture Collection (ATTC). 
2.2 Western Blot 
Western blotting is an important technique used in cell and molecular biology. It 
allows the identification of specific proteins from a complex mixture of proteins 
extracted from cells, based on protein separation according to their molecular 
weight [88]. 
X1 X2 
X1 X2 
Figure 12 - Scheme of the Neubauer 
Chamber. Despite the fact of the recent 
technical development of scientific 
laboratories, the Neubauer chamber remains 
the most common method used for cell 
counting around the world. 
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2.2.1 Total protein extraction 
To get access to the total protein extract present in the cells, we need to rupture 
the cytoplasmic cell membrane allowing all the intracellular components to be 
released. 
Once the cell plates were confluent we washed the cells with 1x PBS and 
collected them. Next, we centrifuged cells at 1100 revolutions per minute (rpm) 
for 4 minutes and discarded the supernatant. 
All the procedures below were performed on ice to preserve the integrity of the 
extracted proteins.  
Protein extraction was made using CST buffer (1 M Tris pH 7.5 (Fisher Scientific, 
EUA), 5 M NaCl (Merck, Germany), 5% Triton X-100 (Amresco, Ohio), 1M NaF 
(VWR, EC), 0.5M EDTA (Sigma Aldrich, USA), 0.5M Ethylene glycol-bis-(β-
aminoethyl ether)-N’,N’,N’,N’-tetraacetic acid (EGTA; AppliChem, Germany), 
200mM Sodium Pyrophosphate (Santa Cruz, Dallas), 1M β-
Glycerolphosphate(β-G-P; Santa Cruz, Dallas), 100mM sodium orthovanadate 
(OVO4; Sigma Aldrich, USA) 0.1 mg/µL Calyculin A (Santa Cruz, Dallas) and 0.1 
mg/µL Protease Inhibitors Cocktail (PIC; Sigma Aldrich, USA)). We added the 
proper volume of CST to the cell pellet and homogenised the samples by pipetting 
up-and-down and a brief vortex. Next, we did a 20-minute incubation of the 
samples on an orbital shaker (Labnet, New Jersey) at 4 ºC. Then we centrifuged 
the samples at 15000 rpm (VWR, Japan) for 20 minutes at 4 ºC. Lastly, we 
transferred the supernatant (where the proteins were) to a new Eppendorf tube. 
2.2.2 Total protein quantification 
Most of the applications throughout this thesis require a rapid and accurate 
method to estimate protein concentration. 
The amount of protein present in our samples was accessed using the Bradford 
(NZYTech, Portugal) method which is a very simple and fast technique based on 
a colorimetric shift of Comassie Brilliant Blue [89]. Moreover, the Bradford assay, 
has also low interference of other substances what makes it very sensitive [90]. 
By comparing the absorbances of our samples with the absorbances of a 
concentration known marker protein (for example Bovine Serum Albumine - BSA; 
ThermoFisher Scientific, USA) we can determine the protein concentration of our 
Study of the TRIB2 protein network 
Catarina Martins Raposo © 2018 
 
26 
 
samples using a standard protein curve. The solutions used are represented in 
Figure 13.  
 
We diluted each of the test samples 1:10 (5 µL of sample in 45 µl of H2O). 
Following, we loaded 5 µL of each test sample (1:10 dilution) and standard curve 
sample into a 96 well plate (in duplicated) and added 250 µL of Bradford to each 
well. The absorbance was measured on a microplate reader (Tecan Life 
Sciences, Austria) using I-control software. Using the absorbance and the linear 
standard curve: y = mx + b, where y=absorbance at 595 nm and x=protein 
concentration we calculated protein concentration for each of our test samples. 
Following, we normalized the protein concentration of all test samples using 
Laemmli 6x (0.2 M TrisHCl (Sigma Aldrich, USA), pH 6.8, 40% glycerol (Sigma 
Aldrich, USA), 0.04% Blue Bromophenol (Santa Cruz, Dallas), 0.3 M SDS 
(Applichem, Germany), 20% β-Mercaptoethanol (Sigma Aldrich, Steinheim)) and 
extraction buffer. Laemmli is a protein-loading buffer that allows the visualization 
of the samples during the run (due to the presence of Blue Bromophenol) and 
simultaneously increases sample density for proper loading (due to glycerol) 
allowing the migration across the gel. The SDS present in the Laemmli charges 
the samples negatively, so the proteins can migrate to the positive pole, being 
separated according to their size. 
Figure 13 – BSA standard curve concentrations To determine the protein 
concentration of our test samples we used a linear standard curve. Serial dilutions 
were obtained from a BSA stock solution at 2000 µg/µL. Letters A to G refer to 
seven different BSA concentrations where A (2 mg/mL BSA), B (1.25 mg/mL BSA), 
C (0.75 mg/mL BSA), D (0.75 mg/mL), E (0.375 mg/Ml BSA), F (0.185 mg/mL BSA) 
and G (0 mg (mL BSA). All dilutions were obtained using H2O  
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Lastly, we heated the samples at 95 ºC in a Thermo Shaker (BioSan) for 5 
minutes. This step allowed for denaturation of the proteins so that they can 
migrate on the gel when applying an electric stimulus. Samples were immediately 
loaded on a gel or stored at -20 ºC. 
 
2.2.3 SDS-PAGE 
The proteins were separated according to their molecular weight, as represented 
in Figure 14, in a sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE; 0.4 M Tris (Sigma Aldrich, USA) pH 8.8, 10% acrylamide (Fisher 
Bioreagents, USA), 0.1% SDS (Applichem, Germany), 0.1% Ammonium 
Persulfate (APS; Sigma Aldrich, USA), 0.15% Tetramethylethylenediamine 
(TEMED; Santa Cruz Biotechnology, Dallas)).  
 
Figure 14 - Differently sized proteins migrate in different speeds across the 
gel. When the voltage is applied, the negative charged molecules migrate 
through the gel in direction to the positive pole. The small proteins in our samples 
migrate easily and the larger proteins are more likely to be retained (migrating 
less). 
 
To obtain optimal protein resolution, we cast a stacking gel over the top of the 
running gel. This allows the proteins in a loaded well to be concentrated into one 
tight band during the first few minutes of electrophoresis before entering the 
running portion of the gel. The stacking gel was prepared with 0.1 M Tris (Sigma 
Aldrich, USA) pH 6.5, 3.8% acrylamide, 0.08% SDS, 0.1% APS, 0,1% TEMED. 
The stacking gel has large sized pores allowing proteins to migrate freely and get 
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stacked at the interface between the stacking and the running gel. This allows for 
proteins to start migration at the same time. 
The choice of the running gel percentage depends on the size of the protein of 
interest as it is shown in Figure 15. 
 
Figure 15 - Separation ranges of proteins in SDS-PAGE. The percentage of 
acrylamide present in the gel determine the speed of migration and the degree of 
separation between the proteins. 
 
After loading the samples, the electrophoresis was performed in SDS-Page 
Running Buffer (0.02 M Tris (Sigma Aldrich, USA)), 0.025 M Glycine (Sigma 
Aldrich, Belgium), and 0.003 M SDS (Applichem, Germany)) using the BIO-RAD 
power source initially at 75 V until proteins enter the running gel and then at 150 
V. 
2.2.4 Protein transfer  
After electrophoresis, the separated proteins present in the gel were transferred 
to a nitrocellulose membrane (Amersham, UK). The SDS-Page Transfer Buffer 
used contained 20% methanol (VWR, France), 0.05M Tris (Sigma Aldrich, USA) 
and 0.05% Glycine (Sigma Aldrich, Belgium). The transference was made using 
the BIO-RAD WB power source at 75 V for 90 minutes. 
 
2.2.5 Blocking step 
The blocking step is important to prevent the antibodies to bind to unspecific 
proteins existing in the membrane surface.  
As blocking reagents, we used 5% BSA (Thermo Scientific, USA) or 5% Milk 
(Nestlé, Portugal). The proteins present in these solutions blocked the 
unoccupied sites on the membrane thus reducing background at detection time 
and improving the signal-to-noise ratio of the assay. This incubation was made 
at room temperature for 1 hour with agitation. 
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2.2.6 Antibodies incubation 
After blocking, the membrane was incubated overnight at 4 ºC using a roller mixer 
(Stuart, UK) with a primary antibody that binds to the target protein, as shown in 
Table 1.  
Table 1 - List of the information about the antibodies used in this project 
Antibody Species Dilution Company #Catalog 
TRIB2 Rabbit 1:800 Cell Signaling Technology 13533S 
p-AKT 473 Rabbit 1:500 Santa Cruz Biotechnology sc-7985-r 
p-AKT 308 Rabbit 1:1000 Cell Signaling Technology 4056S 
t-AKT Rabbit 1:1000 Cell Signaling Technology 9272S 
HA Mouse 1:1000 Cell Signaling Technology 2367S 
MYC Mouse 1:1000 Santa Cruz Biotechnology sc-47694 
GAPDH Rabbit 1:5000 Santa Cruz Biotechnology sc-25778 
Anti-rabbit Donkey 1:10000 GE Healthcare Life Sciences NA931V 
Anti-mouse Sheep 1:1000 GE Healthcare Life Sciences NA934V 
Anti-mouse Light 
Chain Specific Mouse 1:1000 
Cell Signaling 
Technology 58802S 
 
The following day, the membranes were washed to remove residual unbound 
primary antibody, with TBS-Tween (0.075 M Tris (Sigma Aldrich, USA), 0.15 M 
NaCl (Merck Millipore, Germany), 0.1% Tween 20 (Merck Millipore, EC) for three 
times, about 5 minutes each with agitation. We then incubated with the second 
antibody for 1 hour, at room temperature, with agitation. This step allows for the 
first antibody to be recognized and detected.  The membrane was then washed 
with TBS-Tween for three times, 5 minutes each, with agitation. 
2.2.7 Protein detection 
This step allows the detection of the localized probe to document the position and 
the relative abundance of the target protein.  
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The membrane was incubated for 5 minutes in an enhanced chemiluminescence 
(ECL; 1.25 mM Luminol (Sigma Aldrich, USA) diluted in DMSO, 0.2 mM p-
coumaric acid (Sigma Aldrich, UK) diluted in DMSO, 0.1 M Tris pH 8.5, 0.01% 
H2O2 (VWR, EC)). The enzyme HRP (horseradish peroxidase) coupled to the 
secondary antibody luminol is oxidized, in the presence of peroxide, producing 
and excited state product that emits luminescence.  
The signal was detected using the software Image Lab 4.0 of Chemidoc (Bio-
Rad, USA). 
 
2.3 Protein Complementation Assay 
.Protein Complementation Assay (PCA) system has been suggested to be one 
of the most useful tools among the other methods to study protein-protein 
interaction [91]. This system is based on interaction-driven reconstitution of the 
activity of a reporter protein (luciferase, in this case) that is split into two fragments 
as represented on Figure 16. 
 
Figure 16 - Scheme of the PCA structural associations. PCA is a structural 
complementation assay designed for PPIs studies. The system is composed of 
two subunits, Large BiT (LgBiT; 18kDa) and Small BiT (SmBiT; 11 amino acid 
peptide) that are expressed as fusions to target proteins of interest. If these two 
proteins do interact the split fragment of luciferase will come together and give off 
a luminescence signal in the presence of an added substrate Promega Nano-Glo 
Live Cell Assay system (#N2011). 
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We plated 293T cells at a density of 25 000 per 100 µL of standard cell culture 
media in a 96 well plate. We used triplicates for each condition. Cells were 
maintained in standard cell culture incubation for 24 hours. 
The next day, each well was transfected with a total of 100 ng or 150 ng of 
plasmid DNA. We mixed plasmids and top up to 10 µL with serum-free medium. 
We added 2 µL of Fugene6 transfection reagent (Promega #E2691) for each well 
to be transfected. Then we replaced old medium with the transfection mixture and 
incubated for 24 hours at 37 ºC. Next we performed a luciferase assay using 
Promega Nano-Glo Live Cell Assay system (#N2011). Briefly, we discarded the 
medium and carefully washed once with 1x PBS. Added 25 µL of 1x PBS to 
detach all the cells and transferred them to a non-transparent white 96 well plate 
(we left a gap for each condition to avoid signal spillage). We added 25 µL of the 
luciferase reagent to each well and incubated at room temperature for 5 minutes. 
We acquired the luminescence reading on microplate reader (Tecan Life 
Sciences, Austria) using the I-control software.  
The data analysis was done using Microsoft Office Excel.  
2.4 PCA Optimization 
Every protein of interest could be linked to the Small or the Large luciferase 
fragment in its amino or carboxyl termination, so it is crucial to optimize the PCA 
system in order to obtain the best luminescence signal. The optimization was 
done by testing every possible combination of these constructs, represented on 
Figure 17. 
All of the constructs used in the PCA were a kind gift from our collaborator 
Dr.Endre Kiss-Tooth from the University of Sheffield. The results from the 
optimization step are described in the section of the Results.  
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2.5 Plasmid amplification 
The process of plasmid amplification is normally used to replicate or clone 
plasmids for future applications as transfections. Because of this, nearly all 
plasmids carry both a bacterial origin of replication and an antibiotic resistance 
gene for use as a selectable marker in bacteria. 
2.5.1 Bacterial transformation and plasmid amplification 
Transformation is the process by which foreign DNA is introduced into a cell, in 
this case, into bacteria. We used the DH5 alpha E. Coli Strain of bacteria that 
were stored at -80 ºC. We added 1 µL of DNA to 25 µL of bacteria, mixed the 
tube gently and incubated 30 minutes on ice. Following, the mixture was 
incubated on a 42 ºC water bath for 45 seconds and placed back on ice. Next, 
we added 400 µL of Liquid SOC Medium (NZYTech, Portugal) rich in glucose to 
induce bacteria growing. We incubated the tube for one-hour on a 37 ºC shaking 
incubator (Thrmomixer compact, Eppendorf). Then, we resuspend the pellet and 
Figure 17 - Possible constructs of TRIB2 and AKT. There are four 
possible fusions of the protein of interest to the luciferase fragment. Each 
protein of interest can be cloned next to a Small or Large luciferase fragment 
or fused to either its C' or N' terminal region. 
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plated onto a 10cm LB Agar (NZYTech, Portugal) plate containing the appropriate 
antibiotic. We incubated the plates at 37 ºC overnight. 
The next day we picked one colony of the plate using a pipet tip and grew on 50 
mL of LB Medium with the proper antibiotic. Next, we incubated the solution 
overnight, at 37 ºC and orbital shaking. 
2.5.2 DNA extraction 
After 12/14 hours we extracted the DNA extraction using a Midi Prep Kit (VWR, 
USA). We followed manufactures instructions according to Annex A. 
 
2.6 Immunoprecipitation 
Immunoprecipitation is a method of isolating a specific protein from a complex 
mixture such as a cell lysate. The basic principle is very simple: the protein of 
interest is ‘captured’ by an antibody and then the protein-antigen complex is 
pulled out of the sample by the attachment to a bead. This protocol is used to 
study protein-protein interactions. 
For the immunoprecipitation we used the Anti-Flag M2 Affinity Gel (Sigma 
Aldrich). We used 20 μl of bead slurry per sample. The beads were washed three 
times with CST buffer and the supernatant was carefully removed. We performed 
a blocking step by incubating the beads with a 5% BSA solution for 30 minutes 
at room temperature with gentle agitation. We washed the beads three times with 
CST buffer and the final bead volume was adjusted with CST buffer. We added 
20 µL of bead slurry to each sample and incubated the eppendorf tubes for 3 
hours at 4 ºC. We centrifuged the tubes for 30 seconds and carefully removed 
the supernatant. We repeated the washes for three times using CST.  
Following, we added Laemmli 6x (0,2M TrisHCl (Sigma Aldrich, USA), pH 6.8, 
40% glycerol (Sigma Aldrich, USA), 0.04% Blue Bromophenol (Santa Cruz, 
Dallas), 0.3 M SDS (Applichem, Germany), 20% β-Mercaptoethanol (Sigma 
Aldrich, Steinheim)) and extraction buffer CST. Samples were heated to 95 ºC for 
5 minutes and run on an appropriate percentage SDS-gel. 
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2.7 TRIB KO - CRISPR 
For TRIB2 abrogation we used CRISPR-Cas9 technique. It allows genome 
editing and is a highly specific and efficient technique. CRISPR-Cas9 is based on 
a small guide RNA (sgRNA) that defines the genome target location and Cas9, a 
nuclease that induces double strand breaks at a specific site in the genome. 
Protospacer adjacent motif (PAM) is a 2-6 base pairs immediately adjacent to 
DNA sequence targeted by Cas9, which is crucial to Cas9 to recognize the DNA 
sequence, bind and cleave it [92]. This method causes small non sense mutations 
into the reading frame of the target gene via Non Homologous End Joining 
(NHEJ), a mechanism of repair that joints the two broken ends together leading 
to insertions and deletions. 
The CRISPR-Cas9 system targeting TRIB2 was previously designed, optimized 
and validated by Dr.Bibiana Ferreira. We plated the cells in 6-well plates the day 
before transfection. The next day, we transfected 2µg of plasmid coding for two 
different sgRNAs (gRNA #1 guide sequence: GTTGTCGTCTATAAGGTCCG 
CGG and gRNA#2 guide sequence: TCGAAGAGTTGTCGTCTATA AGG) and 
Cas9. We changed the media the following day and added puromycin two days 
after for 48h to select the cells that contained the plasmid. To get individual clones 
we trypsinized the cells and performed serial dilutions to allow single clones to 
grow individually. Clones were selected by washing the cells twice with 1x PBS 
and individually trypsinized and plated them in two 60mm plates: a) a plate was 
used to extract the protein and test the abrogation of the protein by western blot 
and b) was used to keep a frozen stock. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
 
 
 
 
 
  
  
 
 
Study of the TRIB2 protein network 
Catarina Martins Raposo © 2018 
37 
 
 
3 Results  
Considering that TRIB2 and TRIB3 have different roles in tumorigenesis by 
controlling oppositely the phosphorylation of the Ser473 on AKT: TRIB2 
enhances p-AKT of the Ser473 while TRIB3 decreases the p-AKT Ser473 the 
aim of this project is to understand if TRIB2 and TRIB3 compete for AKT binding. 
 
3.1 PCA optimization 
To test our hypothesis we decided to use the Protein Complementation Assay 
(PCA) as the first method to examine the physical interactions between tribbles 
members and AKT. This strategy was developed and previously described by 
Michnick and colleagues [93, 94] and was validated by Dr Endre Kiss-Tooth, our 
collaborator at the University of Sheffield [87]. 
PCA is based on the interaction-driven reconstitution of the activity of luciferase 
that is split into two fragments (a small one, represented by 1.1 and a large one, 
represented by 2.1), each fragment fused to each of our proteins of interest 
(TRIB2 and AKT or TRIB3 and AKT) in its amino (N) or carboxyl (C) termination. 
Therefore, by using this approach, the interaction of proteins can be visualized in 
live cells. All the constructs used in PCA were a kind gift from Dr Endre Kiss-
Tooth. 
We previously knew from our collaborator that the best luminescence signal for 
the association of TRIB3 and AKT was obtained using the small fragment of 
luciferase fused to the C terminal of TRIB3 (1.1 C-TRIB3) and the large fragment 
of luciferase fused to the C terminal of AKT (2.1 C-AKT). 
To determine which pair of TRIB2 and AKT constructs would give the best 
luminescence signal, we had to test every possible combination of these 
plasmids.  
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To this end, we used 293T cells since the basal expression levels of tribble 
members are very low. The level of expression of tribble members has already 
been evaluated previously by other colleges in our lab, both by western blot and 
real-time PCR. Both expression and protein levels were higher in in melanoma 
cells SK-MEL28, G361 and A375 than in non melanoma cells 293T and U2OS, 
as represented on Figure 18. 
In addition, 293T cells are easy to transfect. Cells were transfected with all the 
possible construct combinations and the luminescence signal was acquired. The 
combinations tested were the following: 
1.1 N-TRIB3 x 2.1-N AKT 
1.1 C-TRIB3 x 2.1 C-AKT 
1.1 N-TRIB2 x 2.1-N AKT 
2.1 C-TRIB2 x 1.1-N AKT 
2.1 C-TRIB2 x 1.1 C-AKT 
2.1 N-TRIB2 x 1.1-N AKT 
2.1 N-TRIB2 x 1.1 C-AKT 
1.1 N-TRIB2 x 2.1 C-AKT 
Figure 18 - Presence of tribble members in melanoma and non-melanoma cell lines. 
A) Western blot showing protein levels of Tribble family members in melanoma cell lines 
SK-MEL28, G361 and A375 and non-melanoma cell lines 293T and U2OS. Protein levels 
were assessed with Tribble specific antibodies. Tubulin was used as a loading control. 20 
µg total protein loaded per lane and separated by 10% SDS-PAGE. B). Tribble members 
(TRIB1, TRIB2 and TRIB3) mRNA levels of melanoma A375, G361 and SK-MEL28 and non 
melanoma cell lines 293T and U2OS. mRNA expression levels were evaluated using RT-
PCR and data was analysed using Bio-Rad CFX manager 3.1 software. 
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The results in Figure 19 show that from all construct combinations the pairs 1.1 
N-TRIB2 x 2.1 N-AKT and 1.1 N-TRIB2 x 2.1 C-AKT produced a significantly 
higher luminescence signal. These pairs were followed by 2.1 N-TRIB2 x 1.1 C-
AKT, 2.1 C-TRIB2 x 1.1 N-AKT, 2.1 C-TRIB2 x 1.1 C-AKT and finally by 2.1 N-
TRIB2 x 1.1 C-AKT. 
The best luminescence signal was obtained using the small fragment of luciferase 
fused to the N terminal of TRIB2 (1.1 N-TRIB2) and the large fragment of 
luciferase fused to the N terminal of AKT (2.1 N-AKT). 
Despite of having higher luminescence signal using the 1.1 C-TRIB23 x 2.1 C-
AKT we chose to use the combination of TRIB3 and AKT that had the most similar 
signal to the pair of TRIB3 and AKT: 1.1 N-TRIB2 x 2.1 N AKT, highlighted with 
a red arrow in Figure 19. For this reason, the following experiments were 
performed using these two pairs of constructs:  
1.1 N-TRIB3 x 2.1 N-AKT and 1.1 N-TRB2 x 2.1 N-AKT  
 
 
Figure 19 - PCA optimization. PCA is based on the interaction of two luciferase 
fragments, a small one (represented by 1.1) and a large one (represented by 2.1). 
Each one of these fragments can be fused to AKT or to TRIB2 in their amino (N) 
or carboxyl termination (C). We transiently transfected 293T cells for 24 hours 
using different pairs of constructs. At the end point we added the luciferase 
substrate for 5 minutes and acquired the luminescence signal. As negative 
control we used non-transfected cells (Untransfected) and cells transfected with 
an empty backbone (Nano-bit). RLU means Relative Luminescence Units. Data 
is represented as mean ± SEM; n = 3. P-values were obtained from Dunnett's 
Multiple Comparison Test; (***) P < 0.0001. ns means non-significant. 
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3.2 TRIB3 is able to disrupt TRIB2-AKT association 
Our main goal was to test if TRIB2 and TRIB3 compete for AKT binding. In this 
sense we decided to analyse TRIB2-AKT association in the presence of 
increasing amounts of TRIB3 (from 10 ng to 50 ng). All transfections were 
performed with same amount of total DNA (150 ng) as represented in Table 2. 
 
 
PCA results, represented in Figure 20, show that the luminescent signal 
decreased 45.2% in the presence of 40 ng and by 85% in the presence of 50 ng 
of TRIB3 (highlighted with a red arrow). These results are an indication that the 
strength of the TRIB2-AKT association is compromised by the increasing 
amounts of TRIB3. These data suggests that TRIB3 is able to disrupt the 
association between TRIB2 and AKT. 
Table 2 - Amount of DNA transfected into 293T to analyse TRIB2 and 
AKT interaction in the presence of TRIB3. Cells were transfected with 50 
ng of TRIB2 and 50 ng of AKT. The amount of TRIB3 varied from 0 to 50 ng. 
The empty backbone (Nano-bit) was transfected as the remaining amount 
to a total of 150 ng. 
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Figure 20 - The association between TRIB2 and AKT can be disrupted by 
TRIB3. We transiently transfected 293T cells with the indicated constructs for 24 
hours. At the end point we added the luciferase substrate for 5 minutes and 
acquired the luminescence signal. As negative control we used non-transfected 
cells (Untransfected) and cells transfected with an empty backbone (Nano-bit). 
RLU means Relative Luminescence Units. Data is represented as mean ± SEM; 
n = 3. P-values were obtained from Dunnett's Multiple Comparison Test; (***) P 
< 0.0001. ns means non-significant. 
  
 
3.3 TRIB2 stabilizes TRIB3-AKT interaction 
To investigate if TRIB2 can disrupt TRIB3-AKT interaction, we decided to perform 
the opposite experiment, increasing the quantities of TRIB2 (from 10 ng to 50 ng) 
and analyse the dynamic interaction between TRIB3 and AKT using the PCA 
method.  
Like in the previous experiment we transfected 293T cells with different 
constructs, always maintaining the total amount of DNA transfected (150 ng) as 
represented in Table 3. 
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Surprisingly, the results presented in Figure 21, show that there is a stronger 
association between TRIB2 and AKT in the presence of increasing amounts of 
TRIB3. The luminescent signal increased 75% with 20 ng and 109% with 40 ng 
TRIB2. In contrast, in the presence of 50 ng of TRIB2 the luminescent signal 
dropped almost to the level of the control in the absence of TRIB2. 
Figure 21 - The association between TRIB3 and AKT is stabilized by TRIB2. 
For this experiment we used 293T cell line. We did a 24h transiently transfection 
and acquired the luminesce 24 hours later, after 5 minutes exposure do luciferase 
substrate. As control we transfected only TRIB3 and AKT (absence of TRIB2), 
represented in the green bar. RLU means Relative Luminescence Units. Data are 
Table 3 - Amount of DNA transfected into 293T cells to analyse TRIB3 
and AKT interaction in the presence of TRIB2. 293T were transfected 
with 50 ng of TRIB3 and 50 ng of AKT. The amount of TRIB2 varied from 0 
to 50 ng. The empty backbone (Nano-bit) was transfected as the remaining 
amount to a total of 150 ng. 
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represented as mean ± SEM; n = 3. P-values were obtained from Dunnett's 
Multiple Comparison Test; (***) P < 0.0001. ns means non-significant. 
 
Taken together, the data obtained from the PCA experiments showed that TRIB3 
is able to disrupt TRIB2 and AKT association. On the other hand, increasing 
amounts of TRIB2 do not seem to weaken TRIB3-AKT association. Moreover, 
TRIB2 seems to strengthen TRIB3 and AKT interaction. These experiments also 
showed that AKT preferentially binds TRIB3 over TRIB2. 
Then we wanted to know a) if the disruption between TRIB2 and AKT in the 
presence of increasing amounts of TRIB3 would reflect a decrease in the 
phosphorylation of the Ser473 of AKT and b) if the stabilization of the association 
of TRIB3 and AKT caused by increasing amounts of TRIB2 would reflect a 
decrease in the AKT activation. To this end, we decided to analyse the AKT 
activation measuring the levels of phosphorylation of Ser 473 and Thr308. Note 
that the gel loading control was unequal and therefore the results, present in 
Figure 22, are not conclusive. We repeated the experiment on three different days 
and yet we did not achieve a reliable gel loading. 
Figure 22 – Analysis of AKT activation. For this experiment we performed a 
24h transient transfection in 293T cells of increasing amounts of TRIB2 (panel A) 
and increasing amounts of TRIB3 (panel B). As controls, we used the 293T 
parental cell line (represented as 293T) and 293T transfected with an empty 
backbone (represented as Empty). Cells were lysed and proteins were extracted. 
40 µg of total protein was loaded per lane and separated by 10% SDS-PAGE. 
The protein levels were assessed by western blot using specific antibodies 
against TRIB2 and TRIB3 (represented on the first band on the left and right, 
respectively), p-AKT Thr308, p-AKT Ser473, total AKT (t-AKT) and GAPDH. 
GAPDH was used as a loading control. 
A) B) 
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The only two lanes that are comparable in panel in panel B are those resulting 
from transfection of 50 ng of TRIB3 and 500 ng of TRIB3, represented on Figure 
22, labelled with a red arrow. In these two lanes it is visible that in the presence 
of 500 ng of TRIB3 there is less activation of AKT measured by the 
phosphorylation of Ser473, compared to cells with less TRIB3 (50 ng). These 
results also support the PCA data previously shown on Figure 20. 
3.4 293T stable cell line expressing TRIB2 
To overcome the recurrent problem with gel loading which we hypothesized to be 
caused by the large amount of different DNA transfected into these cells, we 
decided to use a stable expression system to limit the number of constructs to be 
transfected. We used a 293T cell line stably expressing TRIB2 to analyse the role 
of TRIB3 on AKT activation. Unlike the short-term protein expression observed 
during transient transfections, generating stable cell lines enables long-term 
protein expression studies. Moreover, repeating experiments in these cells as 
opposed to transiently-transfected cells increase reproducibility as it eliminates 
the variation associated with repeated transient transfections. 
We transfected 293T cell line with a TRIB2 FLAG tagged plasmid and an empty 
vector plasmid. Figure 23 shows that this 293T cell line stably express TRIB2.  
 
 
Figure 23 - 293T stable cell line expressing TRIB2. For this experiment we 
used 293T cell line. The stable transfection of TRIB2 enables the expression of 
TRIB2 on 293T cells that normally have none or low expression of this protein. 
As transfection controls we used the 293T parental cell line (represented as 
Parental) and cells transfected with an empty backbone (represented as 
EMPTY); 40 µg total protein loaded per lane and separated by 10% SDS-PAGE. 
Protein levels were assessed with the specific tribbles antibodies by western blot 
technique. GAPDH was used as a loading control. MW means molecular weight. 
MW 
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By using these stable cell lines for co-immunoprecipitation, we investigated if the 
strenght of the association between TRIB2 and AKT is compromised in the 
presence of TRIB3, as suggested by the data obtained by the PCA experiments. 
Co-immunoprecipitation is a technique widely used for the analysis and validation 
of protein-protein interactions. 
We transiently transfected increasing amounts of TRIB3, from 50 ng to 1000 ng, 
together with 500 ng of AKT into 293T cells stably expressing TRIB2-FLAG or 
empty parental vector. The immunoprecipitation was performed using specific 
anti-FLAG M2 Sepharose Beads (TRIB2 tag). M2 is a mouse monoclonal 
antibody that recognizes the FLAG sequence at the N-terminus of TRIB2. This 
allows the detection and capture of fusion proteins containing a FLAG peptide 
sequence, as TRIB2. 
The results are represented in Figure 24. By using a cell line that stably expresses 
TRIB2 allowed us to a) have all the experimental conditions expressing TRIB2 at 
the same level and b) reduce the amount of total DNA transfected into the cell.  
The blots for the whole extract (WE) confirmed the presence of TRIB2 in the 293T 
cell line, the transient transfection of AKT and the increasing amounts of TRIB3. 
The blots showing the immunoprecipitated fraction shed doubt on the specificity 
of the beads used to precipitate TRIB2 since, in cell lysates where TRIB2 is not 
present as in lane 2 of the IP blot, a band corresponding to AKT and TRIB3 is 
clearly visible. In the absence of TRIB2, this result might be explained by a) a 
poor washing procedure leaving unspecific cell components stuck to the beads 
or b) unspecific binding properties of the beads. As washing was performed in a 
very stringent and established manner, unspecific binding to the beads seems to 
be a reasonable explanation.  
Study of the TRIB2 protein network 
Catarina Martins Raposo © 2018 
 
46 
 
Figure 24 - Co-immunoprecipitation of FLAG to detect the association of 
TRIB2 to AKT in the presence of increasing amounts of TRIB3. Experiment 
done in 293T lysates from cells stable transfected with TRIB2. Cells transiently 
transfected with increasing amounts of TRIB3 (MycHist-tagged), 500 ng of AKT 
(HA-tagged) and the remaining amount until 1500 ng transfected with an empty 
backbone (pcDNA). The first three blots correspond to immunoprecipitated cell 
lysates with FLAG M2 beads (IP M2) and the last four blots correspond to the 
whole extract (WE) of cell lysates 40µg total protein loaded per lane and 
separated by 10% SDS-PAGE. Protein levels were assessed with the specific 
antibodies by western blot technique. GAPDH was used as a loading control. MW 
means molecular weight. 
 
3.5 UACC-62: TRIB2 KO 
For further experiments we will use a more representative system of melanoma, 
UACC-62 melanoma cell line to test our hypothesis that TRIB2 and TRIB3 
compete for AKT binding. We need a system where TRIB2 and TRIB3 are 
normally expressed to study the consequences of TRIB2 abrogation. To generate 
such a cell system, we decided to abrogate TRIB2 expression using CRISPR-
Cas9 technique, producing knock outs (KO). This technique allows highly specific 
 
 
MW 
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and efficient genome editing. The CRISPR-Cas9 system targeting TRIB2 was 
previously designed and validated in our laboratory. 24 hours after plating the 
cells in 6-well plates, we transfected a plasmid coding simultaneously for single 
guide RNA (sgRNA) against TRIB2 and Cas9. Individual clones of TRIB2 KO 
containing the plasmid were selected using the antibiotic puromycin and tested 
through the analysis of protein expression by western blot using a specific 
antibody of TRIB2, as shown on Figure 25. 
 
In this cell line we obtained several TRIB2 KO with complete TRIB2 abrogation: 
#11, #27 and #29 (generated using sgRNA #1) and #17, #25, #28, #34 and #35 
(using sgRNA #2). For further experiments we can use any of these clones. 
 
 
 
 
 
Figure 25 - TRIB2 KO UACC-62 cell line. The fourth lane shows UACC-
62 parental cell line. The other lanes correspond to different clones for 
TRIB2 KO, using two different guide RNAs targeting two different 
sequences of aminoacids of TRIB2 protein. All the clones were positive 
KO for TRIB2. 40 µg total protein loaded per lane and separated by 10% 
SDS-PAGE. Protein levels were assessed with the specific antibodies by 
western blot technique. GAPDH was used as a loading control. MW 
means molecular weight. 
MW 
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4 Discussion 
Melanoma is the deadliest skin cancer. The majority of patients fail to respond to 
primary therapy or relapse within a year [95, 96]. Understanding the resistance 
mechanisms underlying melanoma resistance can be crucial to the development 
of new therapeutic approaches. Activation of AKT pathway is one of the most 
frequent events in melanoma, the phosphorylation of the Ser473 of AKT is 
correlated with poor clinical outcomes and resistance to melanoma treatment [21, 
22, 24]. Based on the recent findings of our group that high TRIB2 protein levels 
were correlated with high AKT activation and taking into account the discoveries 
of our collaborators from Spain that TRIB3 seem to have the opposite effect on 
AKT, preventing its activation, we hypothesized that TRIB2 and TRIB3 
compete for AKT binding [82, 85]. 
To test the dynamic interaction between TRIB2 and TRIB3 with AKT we chose 
two independent approaches. We used the Protein Complementation Assay 
(PCA) and co-immunoprecipitation experiments. The first experiments using the 
PCA technique revealed that the best luminescence signal obtained for the 
association between TRIB3 and AKT was using the small fragment of luciferase 
fused to the C-terminal of TRIB3 (1.1 C TRIB3) and the large fragment of 
luciferase fused to the C-terminal of AKT (2.1 C AKT). These results are in 
agreement with previous findings from Dr.Endre Kiss-Tooth group showing that 
the N-terminal of TRIB1 and TRIB3, but not of TRIB2, appear to be responsible 
for the nuclear localisation of these proteins. Therefore, the fusion of the fragment 
of luciferase to the C-terminal domain of TRIB3 leaves its N-terminal ‘free’, 
contributing to maintain its function [97]. 
TRIB2 and TRIB3 association with AKT had the strongest signal using the small 
fragment of luciferase fused to the N-terminal of TRIB2 (1.1 N TRIB2) and the 
large fragment of luciferase fused to the N-terminal of AKT (2.1 N AKT). 
Dr.Endre’s group showed in previous studies that the C-terminal domain of TRIB2 
may have unique functions as, unlike in other tribbles family members, its deletion 
leads to the exclusion of TRIB2/MAPKK complexes from the nucleus [97]. 
Therefore, leaving the C-terminal domain of TRIB2 free from the luciferase 
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fragment is crucial to maintain the association with other proteins from the MAPK 
signaling pathway. In fact, our experiments revealed that when we used the 
constructs where luciferase is fused to the C-terminal domain of TRIB2, the 
luminescent signal that measures TRIB2 and AKT association is very low. These 
findings are in line to what has been previously published [97].  
We found that TRIB3 is able to disrupt TRIB2 and AKT association. Recently, 
it has been shown that tribbles proteins compete for MAPK binding, but our data 
shows for the first time that tribbles members may also compete for AKT binding 
[87]. Moreover, recent studies showed that TRIB3 has an important role in the 
suppression of the tumorigenic process by controlling the levels of AKT 
phosphorylation by mTORC2 [79, 98]. Our findings suggest that the tumor 
suppressive activity of TRIB3 relies on its ability to disrupt the association 
between TRIB2 and AKT thus inhibiting the phosphorylation of the serine 473 on 
AKT by mTORC2. This suggestion is in concordance with findings from Velasco’s 
and colleagues that suggest that the loss of TRIB3 produces an increase in the 
phosphorylation of AKT, thus contributing to the malignant progression of 
melanoma [79]  
Our data also showed that increasing amounts of TRIB2 stabilize TRIB3-AKT 
interaction. This result was unexpected and there are no reports in the literature 
about this reciprocal interaction. One possibility that might explain this 
observation refers to cells that express low levels of TRIB3 depend more on 
TRIB2 to enhance AKT activation. On the other hand, in a cellular system 
expressing high TRIB3 levels, TRIB3 preferentially interacts with AKT preventing 
its activation. These experiments also suggest that AKT has a higher binding 
affinity for TRIB3 rather than TRIB2.  
Since high levels of TRIB2 induce Ser473 AKT phosphorylation [82], we sought 
to understand if the decrease in the strength of TRIB2 and AKT association 
caused by TRIB3 presence would also reflect a decrease in the Ser473 AKT 
phosphorylation. Simultaneously, we also checked if a stronger TRIB3-AKT 
association induced by increasing levels of TRIB2 modulated AKT 
phosphorylation status. 
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Unfortunately, our results were not conclusive. The gel loading control was 
unequal probably due to the large amount of different DNAs transfected into 293T 
cells.  
Despite these technical problems, the comparable lanes showed that cells 
transfected with more TRIB3 have less AKT activation. These results support our 
PCA data and suggest, once again, that TRIB3 is able to disrupt TRIB2-AKT 
interaction. Moreover, disturbing this protein complex results in less AKT 
activation and reinforces TRIB3 role as a tumor suppressor as it has been 
previously reported [98].  
To overcome this technical problem, we used a 293T cell line stably expressing 
TRIB2, previously generated in our lab by Dr.Bibiana Ferreira. Hence, the total 
amount of DNA to be transfected can be reduced and the levels of TRIB2 
expressed are normalized in all experimental conditions. We have tried to validate 
the PCA results by analysing TRIB2-AKT association in the presence of TRIB3 
using co-immunoprecipitation technique. The blots of the immunoprecipitated 
lysates were not conclusive and suggest that the beads used were not specific 
for TRIB2 in these cell line. 
TRIB2 KO was performed in UACC-62 melanoma cell line, since it has high 
endogenous TRIB2 levels. We successfully abrogate TRIB2 and these cells will 
be used for following experiments regarding this topic 
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5 Conclusion and Future Perspectives 
Melanoma is the deadliest form of skin cancer, being responsible for 80% of skin 
cancer deaths [99]. The identification and characterization of the principal 
pathways involved in melanoma progression is key to develop new and better 
therapies. Genetic analysis show that there are two frequently mutated signaling 
pathways in melanoma: MAPK pathway and PI3K/AKT pathway [21, 100]. The 
activation of PI3K/AKT pathway is one of the most frequent events in cancer and 
it is correlated with poor clinical outcomes and resistance mechanisms to MAPK 
pathway inhibitors used for melanoma treatment [21, 22]. The Link lab has 
discovered a novel mechanism of drug resistance facilitated by the oncoprotein 
TRIB2 via its direct interaction with AKT and consequently, AKT activation. 
TRIB3, another member of tribbles family, has been proposed to exert the 
opposite effect on AKT, acting as an inhibitor of the phosphorylation of AKT and 
suggesting TRIB3 as a tumor suppressor [98]. Taking this into account, this 
project established an effort to understand if TRIB2 and TRIB3 compete for AKT 
binding. 
Our data suggests for the first time that tribbles members TRIB2 and TRIB3 
compete for AKT binding. Moreover, we suggest that the tumor suppressive 
activity that has been related to TRIB3 relies on its ability to disrupt the 
association between TRIB2 and AKT thus inhibiting AKT activation. Further 
studies are needed to understand the exact mechanism by which TRIB3 affects 
TRIB2 and AKT interaction. 
Our data also suggests that only in a system with low TRIB3 levels TRIB2 is able 
to bind and activate AKT. It proposes that AKT has a higher binding affinity for 
TRIB3 rather than TRIB2. 
In summary, despite the advances in the field of melanoma treatment in the past 
few years, most melanoma patients will eventually relapse. It is fundamental to 
study the resistance mechanisms associated with the administration of the 
current drugs for the development of better treatment options and strategies 
conceived for each patient.  
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TRIB2 was already suggested as a biomarker that predicts clinical responses to 
melanoma treatment [12]. Here, we show evidences that levels of TRIB3 should 
be maintained in cells to avoid TRIB2 oncogenic functions.  
Future research may be focused on the exact molecular mechanism by which 
TRIB3 disrupts TRIB2 and AKT interaction. Hopefully, in the future the malignant 
consequences of high levels of TRIB2 expression in melanoma cells, may be 
counteracted by the oncossupressive protein TRIB3. 
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